Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,351 matching trials from the live ClinicalTrials.gov search.

Filters: New Haven, Connecticut Clear all

Conditions: Aortic Valve Stenosis
Interventions: Medtronic Transcatheter Aortic Valve 2.0 Replacement System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: New Haven, Connecticut • Kansas City, Kansas • Boston, Massachusetts + 4 more

Conditions: Coronary Artery Disease
Interventions: Shockwave Medical Coronary IVL System; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 34
States / cities: Loma Linda, California • Los Angeles, California • San Francisco, California + 26 more

Conditions: Plasma Cell Leukemia
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 11
States / cities: La Jolla, California • New Haven, Connecticut • North Haven, Connecticut + 8 more

Conditions: Healthy Participants
Interventions: PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Interventions: PF-08046033; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 2 more

Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions: [177Lu]Lu-DOTA-TATE, Octreotide LAR; Radiation · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 20
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more

Conditions: FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 25 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1083
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more

Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Sotorasib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 828
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 561 more

Conditions: Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Interventions: Embolization; Procedure
Lead sponsor: Maastricht University; Other
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Triple-negative Breast Cancer
Interventions: Breast surgery, Magnetic resonance imaging, Mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 179
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Antioch, California + 141 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 884
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more

Conditions: Breast Cancer
Interventions: Tomosynthesis digital mammography imaging system; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 2 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 783
States / cities: Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more

Conditions: PTSD, Stress, Psychological, Gunshot Wound
Interventions: Screening Tool for Relief of Trauma (START), standard of care; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Drug Dependence
Interventions: Primary Care Counseling, Cognitive-behavioral psychotherapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pneumonia, Pulmonary Edema, Dyspnea
Interventions: Lung ultrasound, ultrasound; Procedure · Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Overweight, Obesity
Interventions: Eloralintide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 56 more

Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions: favezelimab/pembrolizumab, pembrolizumab, lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more

Conditions: End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions: Pain Coping Skills Training (PCST), Buprenorphine; Behavioral · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more

Conditions: Healthy Participants
Interventions: PF-07321332/ritonavir, Ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Open Surgery, Lymphedema, Free Tissue Transfer, Microsurgery, Anastomosis, Surgical
Interventions: Symani Surgical System; Device
Lead sponsor: MMI (Medical Microinstruments, Inc.); Industry
Eligibility: 22 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • New Haven, Connecticut • Tampa, Florida + 5 more

Conditions: Facial Vascularized Composite Allotransplantation, Functional Recovery
Interventions: Facial Vascularized Composite Allotransplantation (VCA); Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more

Conditions: Advanced Solid Tumor
Interventions: SNV1521, DB-1310, Abiraterone, Darolutamide; Drug
Lead sponsor: ParVation Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 266
States / cities: Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 200 more

Search by objective public record fields.

The Medtronic TAVR 2.0 US Clinical Study

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

The DRAGON 2 Trial

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Relief of Symptoms of Post-traumatic Stress for Victims of Gun Violence

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

Facial Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

SNV1521 in Participants With Advanced Solid Tumors

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung